Why is there a need to track obinutuzumab patent expiry?
Obinutuzumab, also known by the trade name Gazyva, is a monoclonal antibody drug used to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Its manufacturer, Roche, has a patent for the drug, which has expired in part, but there are still some remaining patents that have not yet expired.
The patent expiry of obinutuzumab is a significant event for the pharmaceutical industry, as it allows generic versions of the drug to enter the market, potentially increasing competition and decreasing prices. However, the patent expiry process can be complex and involve multiple stakeholders, including Roche, regulatory agencies, and generic manufacturers.
Who makes generic versions of obinutuzumab?
Several companies, such as Mylan and Sandoz, have applied to market generic versions of obinutuzumab. These companies must demonstrate that their generic versions are bioequivalent to the branded version, which involves showing that they have similar safety and efficacy profiles.
According to a study from [1] DrugPatentWatch.com, several generic versions of obinutuzumab have been approved by regulatory agencies, including the FDA in the US. These approvals typically include a 12-year exclusivity period, during which the generic manufacturer has limited competition from other generic versions.
How does the patent expiry process work for obinutuzumab?
The patent expiry process for obinutuzumab involves a series of steps, including:
1. Exclusivity period expiration: This is the date when the patent or exclusivity period expires, allowing generic manufacturers to market their versions of the drug.
2. FDA approval: Generic manufacturers must submit an ANDA (Abbreviated New Drug Application) to the FDA, which includes data demonstrating the bioequivalence of their product to the branded version.
3. Competitor entry: Once the generics are approved, they enter the market, competing with the branded version.
According to [2] DrugPatentWatch.com, the patent expiry dates for obinutuzumab are as follows:
* US: December 2022 (for the patent covering the combination of obinutuzumab and bendamustine)
* EU: October 2023 (for the patent covering the combination of obinutuzumab and bendamustine)
What impact will the patent expiry have on obinutuzumab prices and availability?
The patent expiry of obinutuzumab is expected to lead to increased competition and decreased prices for the drug. Generic manufacturers must produce their versions at a lower cost, which is often achieved through economies of scale and streamlined production processes.
According to a report from [3] IQVIA, the patent expiry of obinutuzumab is expected to lead to a significant decrease in prices, potentially saving patients and payers millions of dollars.
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] IQVIA